Anzeige
Meldung des Tages: Der nächste Lithium-Runner? EMP startet entscheidende Engineering-Phase

Biogen News

Aktie
WKN:  789617 ISIN:  US09062X1037 US-Symbol:  BIIB Branche:  Pharmazeutika Land:  USA
184,24 $
-0,54 $
-0,29%
161,32 € 20:29:48 Uhr
Depot/Watchlist
Marktkapitalisierung *
22,04 Mrd. €
Streubesitz
3,72%
KGV
11,76
Nachhaltigkeits-Score
49 %
Index-Zuordnung
Nasdaq 100
Weiter abwärts? Short handeln - Jetzt mit Hebel 6,30: VC1QZT
Werbung

Biogen News

17.11.25 - GlobeNewswire
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
Positive CHMP opinion is based on data from the DEVOTE study which evaluated the high dose regimen of nusinersen in treatment-​naive participants and those transitioning from ...
14.11.25 - GlobeNewswire
Biogen Completes Acquisition of Alcyone Therapeutics
CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Alcyone Therapeutics, a clinical-​stage biotechnology ...
03.11.25 - GlobeNewswire
Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025
Oral presentation to share first-​of-its-kind longitudinal gene expression data in IgA nephropathy, unveiling novel insights into the mechanism of action of felzartamab and advancing ...
30.10.25 - wallstreetONLINE Redaktion
Ihre wichtigsten Termine: Apple, Mastercard, Eli Lilly, Biogen, VW, Wacker Chemie und Lufthansa im Fokus!
Gut geplant in den Tag. Mit dem wO-​Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine ...
25.10.25 - wallstreetONLINE Redaktion
Gewinner der Börsengeschichte: US-Biotech-Perle: +37.497 % in 30 Jahren: Aus 1.000 wurden 375.000 USD!
Nicht Nvidia, Amazon, Netflix oder Apple. Ein börsennotiertes Biotech-​Unternehmen aus Massachusetts hat Aktionären innerhalb von 30 Jahren +37.497 Prozent Rendite gebracht. ...
24.10.25 - GlobeNewswire
Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio
The oral C5aR1 antagonist is designed to modulate neutrophil-​driven inflammation, a central mechanism underlying many inflammatory diseases CAMBRIDGE, Mass. and ...
22.10.25 - GlobeNewswire
Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
Dapirolizumab pegol (DZP) Phase 3 study presentations in SLE to show efficacy results across multiple clinical endpoints, including low disease activity/remission, flares, fatigue, ...
14.10.25 - GlobeNewswire
LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”
TOKYO and CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Headquarters ...
13.10.25 - PR Newswire
LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"
LEQEMBI® IQLIK™(lecanemab-​irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025" PR Newswire
09.10.25 - GlobeNewswire
Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
– An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improvements in cognition and behavior at 2 years; results ...
06.10.25 - GlobeNewswire
Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer’s Disease
New LEQEMBI Companion ™ program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with ...
06.10.25 - PR Newswire
Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-​irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease PR Newswire
03.10.25 - dpa-AFX
Erste Patienten bekommen Alzheimer-Mittel Lecanemab
Seit gut einem Monat ist das Alzheimer-​Medikament Lecanemab der Hersteller Biogen und Eisai in Deutschland verfügbar - inzwischen haben erste Patientinnen und Patienten mit ...
29.09.25 - GlobeNewswire
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in China
TOKYO and CAMBRIDGE, Mass., Sept. 28, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate ...
25.09.25 - dpa-AFX
EU erteilt Zulassung für Alzheimer-Medikament von Eli Lilly
Für einen Teil der Menschen mit Alzheimer im Frühstadium gibt es in der EU eine weitere Behandlungsmöglichkeit. Die zuständige Europäische Kommission erteilte dem ...
24.09.25 - GlobeNewswire
LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia
TOKYO and CAMBRIDGE, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate ...
23.09.25 - GlobeNewswire
Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen
CAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) issued a Complete ...
18.09.25 - GlobeNewswire
Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates
Biogen to drive end-​to-end development and commercialization of ThecaFlex DRx™, an investigational implantable device for intrathecal delivery of antisense oligonucleotides (ASOs) ...
17.09.25 - GlobeNewswire
Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
Postpartum depression is a leading cause of maternal mortality in Europe 1-2 , and is one of the most common medical conditions associated with pregnancy 3-5 ; up to 20% of ...
17.09.25 - dpa-AFX
Biogen-Medikament gegen Wochenbettdepression in der EU zugelassen
Frauen mit Wochenbettdepression haben in der EU künftig Zugang zu einem neuen Medikament. Die Europäische Kommission hat Zuranolon vom US-​Konzern Biogen die EU-...

Newssuche

Videos

newspaper
19:20 Uhr -1,56%
Technical Trading: Kurzfristig Gold Long
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »